MaxCyte, Inc. (MXCT) AI Stock Analysis
MXCT AI stock analysis summary
AI ResearchMaxCyte, Inc. (MXCT) is a life sciences company providing electroporation systems and consumables for cell therapies. The company generated $31.1M in trailing twelve-month revenue, but operating margin was -140.7% amid ongoing net losses. Despite top-line contraction, MaxCyte maintained a solid balance sheet with $88.4M in net cash as of June 30, 2026.
- Market cap
- $134.2M
- Revenue (TTM)
- $31.1M
- P/E
- —
- 1Y return
- -26.6% S&P 500 16.8%
- Avg. target
- $4.11 216.0% vs last close
Bull case
- MaxCyte held $88.4M in net cash and had a current ratio of 12.26 as of June 30, 2026.
- Analysts estimate revenue will grow 15.5% to $37.2M in the fiscal year following FY2026.
- The company demonstrated execution consistency by beating EPS estimates in each of the last 4 quarters.
Bear case
- Annual revenue contracted in three consecutive years from $44.3M in FY2022 to $33.0M in FY2025.
- Free cash flow remained negative at -$36.2M in FY2025 alongside a trailing twelve-month operating margin of -140.7%.
- MaxCyte stock fell 88.2% over a 5-year period, while the S&P 500 gained 83.0%.
What MaxCyte does
MaxCyte, Inc. is a life sciences company specializing in the advancement and commercialization of next-generation cell therapies. Its product portfolio features electroporation systems, including ExPERT ATx for static electroporation at small to medium scales, ExPERT STx for protein production and cell-based assays, ExPERT GTx for large-scale therapeutic transfection, and ExPERT VLx for very large volume cell engineering. MaxCyte also supplies disposable processing assemblies along with electroporation buffer solutions and software protocols. Founded in 1998 and based in Rockville, Maryland, the company supports cell engineering applications worldwide.
Growth and profitability
MaxCyte delivered revenue of $33.9M in FY2021 and grew to $44.3M in FY2022 before entering three consecutive years of revenue contraction. Revenue dropped to $41.3M in FY2023, $38.6M in FY2024, and fell 14.5% to $33.0M in FY2025. Gross margin contracted from 89.2% in FY2021 to 81.2% in FY2025. Net losses widened over this period, expanding from -$19.1M in FY2021 to -$44.6M in FY2025, while operating margin deteriorated to -137.1%. For the latest quarter ended June 30, 2026, quarterly revenue fell 14.5% year-over-year, contributing to trailing twelve-month revenue of $31.1M and net margin of -114.8%.
Balance sheet and cash flow
As of June 30, 2026, MaxCyte held $105.7M in cash and short-term investments against total debt of $17.3M, yielding net cash of $88.4M. Its liquidity profile shows a current ratio of 12.26 and a debt-to-equity ratio of 0.11 against shareholders' equity of $158.8M. In FY2025, operating cash flow was -$34.4M and free cash flow was -$36.2M, with capital expenditures of $1.8M. Five-year share count increased by 5.9%.
Valuation and performance
At a last close of $1.30 on October 16, 2026, MaxCyte had a market capitalization of $134.2M and an enterprise value of $34.4M. The stock trades at a price-to-sales multiple of 4.3x, slightly above the 4.1x median of its US-listed Healthcare peers, and a price-to-book ratio of 0.8x. Over the past year, the stock fell 26.6%, trailing the S&P 500 (SPY) return of 16.8%. Over five years, MaxCyte lost 88.2%, compared to an 83.0% gain for the benchmark index.
What analysts expect
Wall Street sentiment includes 5 Strong Buy and 1 Hold ratings. The mean price target is $4.11, representing 216.0% upside from the last close of $1.30. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.28 on revenue of $32.2M. For the following fiscal year, 3 analysts project revenue to expand 15.5% to $37.2M with EPS of -$0.25. MaxCyte beat EPS estimates in each of the last 4 quarters, and its next earnings date is November 10, 2026.
Key risks and what to watch
- Quarterly revenue fell 14.5% year-over-year in the period ended June 30, 2026, reflecting ongoing top-line weakness.
- Operating cash outflow expanded to -$34.4M in FY2025, which draws down the $105.7M cash balance.
- Gross margin compressed from 89.2% in FY2021 to 81.2% in FY2025.
- The stock has a beta of 1.49, indicating higher volatility than the broader equity market.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this MXCT AI stock analysis
This page is an AI-written research summary of MaxCyte, Inc. (MXCT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: MXCT income statement, MXCT balance sheet, MXCT key metrics, MXCT analyst forecast, MXCT chart. See the MXCT stock overview for the latest quote and news.
MXCT AI stock analysis FAQ
What products does MaxCyte produce?
MaxCyte provides electroporation systems such as ExPERT ATx, ExPERT STx, ExPERT GTx, and ExPERT VLx. It also sells disposable processing assemblies, buffer solutions, and software protocols for cell engineering.
How much cash and debt does MaxCyte have?
As of June 30, 2026, MaxCyte had $105.7M in cash and short-term investments and $17.3M in total debt, resulting in net cash of $88.4M.
What is the consensus price target for MXCT?
Analysts have a mean price target of $4.11, which is 216.0% above its last close of $1.30 on October 16, 2026.
Does MaxCyte pay a dividend?
MaxCyte does not pay a dividend. The company directs capital toward research and development and operations, posting -$36.2M in free cash flow in FY2025.